Biological E, an Indian pharmaceutical manufacturer, has partnered with China’s Recbio to produce and commercialize the REC603 HPV9 vaccine, marking a significant step in combating HPV-related cancers. Designed to protect against nine strains of Human Papillomavirus (HPV), the vaccine targets cervical, vulvar, vaginal, anal, and oropharyngeal cancers, as well as genital warts. Globally, HPV infections are linked to 620,000 cancer cases in women and 70,000 in men annually.
Under the agreement, Re